In this video, Dr. Aaron Kowalski, Chief Executive Officer of the Juvenile Diabetes Research Foundation (JDRF), presents a compelling testimony before a congressional committee, advocating for the continued support and funding of the Special Diabetes Program (SDP). Dr. Kowalski, a trained scientist with a personal and family history of Type 1 Diabetes (T1D), eloquently shares his journey and the profound impact diabetes has had on his life and those of the delegates present. He underscores the transformative advancements achieved through the SDP, which has not only revolutionized the management of T1D but also brought us steps closer to finding a cure.
Dr. Kowalski's testimony is a powerful blend of personal narrative, scientific insight, and policy advocacy. He highlights the groundbreaking progress made in T1D treatment and management, including the development of therapies that can delay the onset of T1D and the approval of the first cell therapy for adults with T1D who suffer from severe hypoglycemia, allowing some to live without external insulin for years. He attributes these achievements to the SDP's funding and support, emphasizing the program's role in improving the quality of life for those living with T1D and advancing research towards a cure.
Throughout his testimony, Dr. Kowalski acknowledges the bipartisan support from Congress, particularly lauding Senators Collins and Shaheen for their leadership. He stresses the importance of the SDP's renewal, urging swift action to extend its funding through December 2025 to ensure the continuation of vital research and development efforts in the T1D field. Additionally, Dr. Kowalski calls attention to the need for affordable insulin, advocating for the passage of the bipartisan Insulin Act of 2023, which aims to cap monthly insulin costs and make it more accessible to all, regardless of insurance status.
The video not only sheds light on the significant strides made in T1D research and treatment but also serves as a clarion call for sustained legislative and financial support to further these advancements. Dr. Kowalski's passionate plea underscores the critical role of the SDP in fostering innovation, enhancing patient care, and driving towards the ultimate goal of curing T1D. His message is clear: continued investment in diabetes research is essential for saving lives, improving outcomes, and offering hope to millions affected by this chronic condition.